Obexelimab + Obexelimab
Phase 3Active 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Warm Autoimmune Hemolytic Anemia
Conditions
Warm Autoimmune Hemolytic Anemia
Trial Timeline
Sep 25, 2023 → Aug 31, 2026
NCT ID
NCT05786573About Obexelimab + Obexelimab
Obexelimab + Obexelimab is a phase 3 stage product being developed by Zenas BioPharma for Warm Autoimmune Hemolytic Anemia. The current trial status is active. This product is registered under clinical trial identifier NCT05786573. Target conditions include Warm Autoimmune Hemolytic Anemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05786573 | Phase 3 | Active |
Competing Products
12 competing products in Warm Autoimmune Hemolytic Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ianalumab + Placebo | Novartis | Phase 3 | 77 |
| rituximab (Mabthera®) + Placebo | Roche | Phase 3 | 77 |
| rilzabrutinib | Sanofi | Phase 2 | 51 |
| Isatuximab SAR650984 | Sanofi | Phase 2 | 51 |
| parsaclisinib + placebo | Incyte | Phase 3 | 74 |
| RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly | Immunovant | Phase 2 | 49 |
| HMPL-523(300mg PO QD) + Placebo | HUTCHMED | Phase 2/3 | 60 |
| APL-2 | Apellis Pharmaceuticals | Phase 2 | 47 |
| ANX005 | Annexon | Phase 2 | 47 |
| Fostamatinib 150 mg bid | Rigel Pharmaceuticals | Phase 2 | 44 |
| Fostamatinib disodium | Rigel Pharmaceuticals | Phase 3 | 69 |
| Fostamatinib disodium + Placebo | Rigel Pharmaceuticals | Phase 3 | 69 |